BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34854746)

  • 1. Magnetic Resonance Imaging-Guided Biopsy in Active Surveillance of Prostate Cancer.
    Kinnaird A; Yerram NK; O'Connor L; Brisbane W; Sharma V; Chuang R; Jayadevan R; Ahdoot M; Daneshvar M; Priester A; Delfin M; Tran E; Barsa DE; Sisk A; Reiter RE; Felker E; Raman S; Kwan L; Choyke PL; Merino MJ; Wood BJ; Turkbey B; Pinto PA; Marks LS
    J Urol; 2022 Apr; 207(4):823-831. PubMed ID: 34854746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
    Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
    JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
    Klotz L; Loblaw A; Sugar L; Moussa M; Berman DM; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Pond GR; Haider M
    Eur Urol; 2019 Feb; 75(2):300-309. PubMed ID: 30017404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
    BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.
    Nassiri N; Margolis DJ; Natarajan S; Sharma DS; Huang J; Dorey FJ; Marks LS
    J Urol; 2017 Mar; 197(3 Pt 1):632-639. PubMed ID: 27639713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upgrading on Per Protocol versus For Cause surveillance prostate biopsies: An opportunity to decreasing the burden of active surveillance.
    Wang M; Lange A; Perlman D; Qi J; George AK; Ferrante S; Semerjian A; Sarle R; Cher ML; Ginsburg KB;
    Prostate; 2023 Sep; 83(12):1141-1149. PubMed ID: 37173808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
    J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
    J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
    Stonier T; Tin AL; Sjoberg DD; Jibara G; Vickers AJ; Fine S; Eastham J
    J Urol; 2021 Apr; 205(4):1063-1068. PubMed ID: 33216696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Upgrading from Prostate Biopsy to Radical Prostatectomy Pathology-Does Saturation Biopsy of Index Lesion during Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Help?
    Calio BP; Sidana A; Sugano D; Gaur S; Maruf M; Jain AL; Merino MJ; Choyke PL; Wood BJ; Pinto PA; Turkbey B
    J Urol; 2018 Apr; 199(4):976-982. PubMed ID: 29154904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer.
    O'Connor LP; Wang AZ; Yerram NK; Lebastchi AH; Ahdoot M; Gurram S; Zeng J; Mehralivand S; Harmon S; Merino MJ; Parnes HL; Choyke PL; Turkbey B; Wood BJ; Pinto PA
    Urology; 2020 Oct; 144():164-170. PubMed ID: 32679272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.
    Chang E; Jones TA; Natarajan S; Sharma D; Simopoulos D; Margolis DJ; Huang J; Dorey FJ; Marks LS
    J Urol; 2018 Jan; 199(1):98-105. PubMed ID: 28728993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Lai WS; Gordetsky JB; Thomas JV; Nix JW; Rais-Bahrami S
    Cancer; 2017 Jun; 123(11):1941-1948. PubMed ID: 28140460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Gaffney CD; Tin AL; Fainberg J; Fine S; Jibara G; Touijer K; Eastham J; Scardino P; Laudone V; Vickers AJ; Ehdaie B
    Cancer; 2023 Dec; 129(23):3790-3796. PubMed ID: 37584213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of MRI-Targeted in-Bore Prostate Biopsy According to the Gleason Score with Postprostatectomy Histopathologic Control--a Targeted Biopsy-Only Strategy with Limited Number of Cores.
    Garmer M; Busch M; Mateiescu S; Fahlbusch DE; Wagener B; Grönemeyer DH
    Acad Radiol; 2015 Nov; 22(11):1409-18. PubMed ID: 26343218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
    Ren J; Melamed J; Taneja SS; Wysock JS; Huang WC; Lepor H; Deng FM
    Prostate; 2023 Mar; 83(4):323-330. PubMed ID: 36461793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance.
    Tran GN; Leapman MS; Nguyen HG; Cowan JE; Shinohara K; Westphalen AC; Carroll PR
    Eur Urol; 2017 Aug; 72(2):275-281. PubMed ID: 27595378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
    Chesnut GT; Vertosick EA; Benfante N; Sjoberg DD; Fainberg J; Lee T; Eastham J; Laudone V; Scardino P; Touijer K; Vickers A; Ehdaie B
    Eur Urol; 2020 Apr; 77(4):501-507. PubMed ID: 31874726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?
    Mazzone E; Stabile A; Sorce G; Pellegrino F; Barletta F; Motterle G; Scuderi S; Cirulli GO; Cucchiara V; Brembilla G; Esposito A; Gandaglia G; Fossati N; De Cobelli F; Montorsi F; Karnes RJ; Guccini I; Briganti A
    Urol Oncol; 2021 Nov; 39(11):784.e1-784.e9. PubMed ID: 33865687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.